BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12485952)

  • 41. The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein.
    Lin HL; Hollenberg PF
    J Pharmacol Exp Ther; 2007 Apr; 321(1):276-87. PubMed ID: 17251390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of cytochrome P450 2B6 and 2B4 substrate access channel residues predicted based on crystal structures of the amlodipine complexes.
    Jang HH; Davydov DR; Lee GY; Yun CH; Halpert JR
    Arch Biochem Biophys; 2014 Mar; 545():100-7. PubMed ID: 24445070
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein.
    Blobaum AL; Kent UM; Alworth WL; Hollenberg PF
    Chem Res Toxicol; 2002 Dec; 15(12):1561-71. PubMed ID: 12482238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitory monoclonal antibody to human cytochrome P450 2B6.
    Yang TJ; Krausz KW; Shou M; Yang SK; Buters JT; Gonzalez FJ; Gelboin HV
    Biochem Pharmacol; 1998 May; 55(10):1633-40. PubMed ID: 9633999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of substrate metabolism by cytochromes P450 2B1, 2B4, and 2B6: relationship of heme spin state, catalysis, and the effects of cytochrome b5.
    Reed JR; Hollenberg PF
    J Inorg Biochem; 2003 Jan; 93(3-4):152-60. PubMed ID: 12576277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
    Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.
    O'Donnell JP; Dalvie DK; Kalgutkar AS; Obach RS
    Drug Metab Dispos; 2003 Nov; 31(11):1369-77. PubMed ID: 14570769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phencyclidine iminium ion. NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P-450.
    Hoag MK; Trevor AJ; Kalir A; Castagnoli N
    Drug Metab Dispos; 1987; 15(4):485-90. PubMed ID: 2888621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
    Richter T; Schwab M; Eichelbaum M; Zanger UM
    Biochem Pharmacol; 2005 Feb; 69(3):517-24. PubMed ID: 15652242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules.
    Shah MB; Wilderman PR; Pascual J; Zhang Q; Stout CD; Halpert JR
    Biochemistry; 2012 Sep; 51(37):7225-38. PubMed ID: 22909231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanism-based inactivation of cytochrome P450 2B1 by N-benzyl-1-aminobenzotriazole.
    Kent UM; Bend JR; Chamberlin BA; Gage DA; Hollenberg PF
    Chem Res Toxicol; 1997 May; 10(5):600-8. PubMed ID: 9168259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance.
    Zhang H; Lin HL; Walker VJ; Hamdane D; Hollenberg PF
    Mol Pharmacol; 2009 Nov; 76(5):1011-8. PubMed ID: 19720728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
    Casabar RC; Wallace AD; Hodgson E; Rose RL
    Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
    Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
    J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.
    Rae JM; Soukhova NV; Flockhart DA; Desta Z
    Drug Metab Dispos; 2002 May; 30(5):525-30. PubMed ID: 11950782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolism-dependent inactivation of liver microsomal enzymes by phencyclidine.
    Hoag MK; Trevor AJ; Asscher Y; Weissman J; Castagnoli N
    Drug Metab Dispos; 1984; 12(3):371-5. PubMed ID: 6145566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.
    Sridar C; Goosen TC; Kent UM; Williams JA; Hollenberg PF
    Drug Metab Dispos; 2004 Jun; 32(6):587-94. PubMed ID: 15155549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolism of bergamottin by cytochromes P450 2B6 and 3A5.
    Kent UM; Lin HL; Noon KR; Harris DL; Hollenberg PF
    J Pharmacol Exp Ther; 2006 Sep; 318(3):992-1005. PubMed ID: 16785317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
    Heyn H; White RB; Stevens JC
    Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver.
    Hanna IH; Reed JR; Guengerich FP; Hollenberg PF
    Arch Biochem Biophys; 2000 Apr; 376(1):206-16. PubMed ID: 10729207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.